Y Intercept Hong Kong Ltd Trims Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Y Intercept Hong Kong Ltd cut its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 93.4% during the 2nd quarter, Holdings Channel.com reports. The firm owned 12,676 shares of the company’s stock after selling 180,711 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Teva Pharmaceutical Industries were worth $212,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in TEVA. Transcend Capital Advisors LLC increased its stake in shares of Teva Pharmaceutical Industries by 7.6% in the second quarter. Transcend Capital Advisors LLC now owns 13,692 shares of the company’s stock worth $229,000 after buying an additional 973 shares during the last quarter. Solstein Capital LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth about $949,000. Asset Management One Co. Ltd. increased its position in shares of Teva Pharmaceutical Industries by 0.8% in the 2nd quarter. Asset Management One Co. Ltd. now owns 432,240 shares of the company’s stock worth $7,244,000 after purchasing an additional 3,403 shares during the last quarter. ARK Investment Management LLC raised its stake in shares of Teva Pharmaceutical Industries by 33.9% in the 2nd quarter. ARK Investment Management LLC now owns 120,874 shares of the company’s stock valued at $2,026,000 after purchasing an additional 30,621 shares in the last quarter. Finally, FNY Investment Advisers LLC bought a new position in shares of Teva Pharmaceutical Industries during the second quarter worth about $516,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Trading Down 1.9%

Shares of NYSE:TEVA opened at $24.01 on Friday. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The company’s 50-day moving average price is $19.74 and its 200 day moving average price is $17.86. The company has a market cap of $27.53 billion, a PE ratio of -150.03, a P/E/G ratio of 1.11 and a beta of 0.70. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $25.00.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, November 5th. The company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.68 by $0.10. The firm had revenue of $4.48 billion during the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. Teva Pharmaceutical Industries’s quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.69 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. Sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. UBS Group increased their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. Finally, JPMorgan Chase & Co. increased their target price on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $25.86.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.